Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

International MG/COVID-19 Working Group; Saiju Jacob; Srikanth Muppidi; Amanda Guidon; Jeffrey Guptill; Michael Hehir; James F Howard Jr; Isabel Illa; Renato Mantegazza; Hiroyuki Murai; Kimiaki Utsugisawa; John Vissing; Heinz Wiendl; Richard J Nowak

doi:10.1016/j.jns.2020.116803

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

J Neurol Sci. 2020 May 15:412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.

Affiliations

¹ Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: [email protected].
² Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304, USA. Electronic address: [email protected].
³ Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁴ Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.
⁵ Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401, USA.
⁶ Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA.
⁷ Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025, Spain.
⁸ Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy.
⁹ Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.
¹⁰ Department of Neurology, Hanamaki General Hospital, Japan.
¹¹ Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
¹² Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.
¹³ Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: [email protected].

No abstract available

Publication types

Practice Guideline

MeSH terms

Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Clinical Trials as Topic
Coronavirus Infections / complications*
Coronavirus Infections / drug therapy
Coronavirus Infections / epidemiology*
Disease Management
Disease Susceptibility
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / therapeutic use
Immunosuppressive Agents / therapeutic use
Immunotherapy
Lambert-Eaton Myasthenic Syndrome / complications
Lambert-Eaton Myasthenic Syndrome / drug therapy
Lambert-Eaton Myasthenic Syndrome / therapy*
Myasthenia Gravis / complications*
Myasthenia Gravis / drug therapy
Myasthenia Gravis / therapy*
Pandemics*
Plasma Exchange
Pneumonia, Viral / complications*
Pneumonia, Viral / drug therapy
Pneumonia, Viral / epidemiology*
SARS-CoV-2
Vaccines

Substances

Immunoglobulins, Intravenous
Immunologic Factors
Immunosuppressive Agents
Vaccines

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States